![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZCCHC12 |
Gene summary for ZCCHC12 |
![]() |
Gene information | Species | Human | Gene symbol | ZCCHC12 | Gene ID | 170261 |
Gene name | zinc finger CCHC-type containing 12 | |
Gene Alias | PNMA7A | |
Cytomap | Xq24 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6PEW1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
170261 | ZCCHC12 | PTCwithHT_1 | Human | Thyroid | HT | 2.30e-02 | 5.36e-01 | 0.0238 |
170261 | ZCCHC12 | PTCwithHT_8 | Human | Thyroid | HT | 5.27e-10 | 7.11e-01 | 0.0351 |
170261 | ZCCHC12 | PTCwithoutHT_4_2 | Human | Thyroid | PTC | 6.90e-05 | 8.01e-01 | 0.0455 |
170261 | ZCCHC12 | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.88e-19 | 1.24e+00 | 0.0381 |
170261 | ZCCHC12 | male-WTA | Human | Thyroid | PTC | 1.22e-43 | 8.02e-01 | 0.1037 |
170261 | ZCCHC12 | female-WTA | Human | Thyroid | PTC | 4.89e-15 | 8.57e-01 | 0.0726 |
170261 | ZCCHC12 | PTC01 | Human | Thyroid | PTC | 3.39e-79 | 3.22e+00 | 0.1899 |
170261 | ZCCHC12 | PTC04 | Human | Thyroid | PTC | 1.48e-61 | 2.82e+00 | 0.1927 |
170261 | ZCCHC12 | PTC05 | Human | Thyroid | PTC | 1.73e-18 | 1.19e+00 | 0.2065 |
170261 | ZCCHC12 | PTC06 | Human | Thyroid | PTC | 1.10e-50 | 2.37e+00 | 0.2057 |
170261 | ZCCHC12 | PTC07 | Human | Thyroid | PTC | 6.84e-92 | 3.06e+00 | 0.2044 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCCHC12 | SNV | Missense_Mutation | rs756361688 | c.1142N>T | p.Thr381Ile | p.T381I | Q6PEW1 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.666) | TCGA-69-7974-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ZCCHC12 | SNV | Missense_Mutation | c.945N>T | p.Arg315Ser | p.R315S | Q6PEW1 | protein_coding | tolerated(0.85) | benign(0) | TCGA-91-6848-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | CR | |
ZCCHC12 | SNV | Missense_Mutation | c.994N>T | p.Pro332Ser | p.P332S | Q6PEW1 | protein_coding | tolerated_low_confidence(0.12) | benign(0.005) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
ZCCHC12 | SNV | Missense_Mutation | c.829G>A | p.Val277Met | p.V277M | Q6PEW1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-99-7458-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | tarceva | SD | |
ZCCHC12 | SNV | Missense_Mutation | novel | c.665G>T | p.Trp222Leu | p.W222L | Q6PEW1 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-L9-A444-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZCCHC12 | SNV | Missense_Mutation | rs775616873 | c.104N>T | p.Pro35Leu | p.P35L | Q6PEW1 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-MP-A4T4-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZCCHC12 | SNV | Missense_Mutation | c.1174N>T | p.Pro392Ser | p.P392S | Q6PEW1 | protein_coding | tolerated_low_confidence(0.21) | benign(0.181) | TCGA-MP-A4TF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | navelbine | PD | |
ZCCHC12 | SNV | Missense_Mutation | c.781T>A | p.Cys261Ser | p.C261S | Q6PEW1 | protein_coding | tolerated(0.11) | probably_damaging(0.994) | TCGA-18-3411-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ZCCHC12 | SNV | Missense_Mutation | c.558N>T | p.Arg186Ser | p.R186S | Q6PEW1 | protein_coding | tolerated(0.42) | benign(0.059) | TCGA-18-3421-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZCCHC12 | SNV | Missense_Mutation | novel | c.1036N>A | p.Arg346Ser | p.R346S | Q6PEW1 | protein_coding | tolerated(0.37) | benign(0.099) | TCGA-21-1076-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |